FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
FibroBiologics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$0.94−0.03 (-2.77%)
Close on Oct 19, 2026
- Market cap
- $5.92M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.0719 (−88.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.28
- Dividend yield
- –
- Free cash flow yield
- -249.85%
Fundamentals
- Net income
- -$18.14M
- EPS, diluted
- -$5.67
- Free cash flow
- -$14.80M
- Book value per share
- $0.74
- Diluted shares
- 6M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$16.73M
Net income
-$18.14M
EPS, diluted
-$5.67
Free cash flow
-$14.80M
Reported periodTrailing twelve months